A pilot proof of concept study of the Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders (EASi-RAIR)

Brief description of study

The purpose of this research is to study Short Chain Fatty Acids (SCFAs), bacterial fermentation products that are naturally found at varying concentrations in your gut, and how it affects the abundance of microorganisms in your gut, as well as T regulatory cells in your blood. SCFAs are metabolites that are known to change the immune response in animal models of inflammation. This study is important because we hypothesize that changes in the gut microbiome and the regulatory immune response may improve treatment of rheumatoid arthritis (RA).

SCFAs are not an FDA-approved treatment for RA or for any other condition. We are not studying SCFAs as a treatment for your condition. We only want to see the effect of SCFAs on the microorganisms in your gut and on certain blood measures.

Clinical Study Identifier: s22-01526

Principal Investigator: Jose U Scher.

Other Investigator: Rebecca Barbara Blank.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies